4PKB Stock Overview
A clinical-stage immuno-oncology company, focuses on developing cancer treatments. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
LAVA Therapeutics N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.49 |
| 52 Week High | US$3.66 |
| 52 Week Low | US$1.31 |
| Beta | 0.48 |
| 11 Month Change | -16.76% |
| 3 Month Change | -12.35% |
| 1 Year Change | 8.76% |
| 33 Year Change | -74.75% |
| 5 Year Change | n/a |
| Change since IPO | -87.49% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4PKB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.5% | -0.7% | -0.02% |
| 1Y | 8.8% | -17.2% | 8.2% |
Return vs Industry: 4PKB exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 4PKB matched the German Market which returned 8.2% over the past year.
Price Volatility
| 4PKB volatility | |
|---|---|
| 4PKB Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4PKB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4PKB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Steve Hurly | www.lavatherapeutics.com |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.
LAVA Therapeutics N.V. Fundamentals Summary
| 4PKB fundamental statistics | |
|---|---|
| Market cap | €40.41m |
| Earnings (TTM) | -€23.22m |
| Revenue (TTM) | €7.10m |
5.7x
P/S Ratio-1.7x
P/E RatioIs 4PKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4PKB income statement (TTM) | |
|---|---|
| Revenue | US$7.40m |
| Cost of Revenue | US$164.00k |
| Gross Profit | US$7.23m |
| Other Expenses | US$31.42m |
| Earnings | -US$24.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 97.78% |
| Net Profit Margin | -326.89% |
| Debt/Equity Ratio | 12.6% |
How did 4PKB perform over the long term?
See historical performance and comparison